1. Fang, Likui, Yu, Wenfeng, Zhu, Pengfei, Yu, Guocan, Ye, Bo. 2023. TEDC2 correlated with prognosis and immune microenvironment in lung adenocarcinoma. In Scientific reports, 13, 5006. doi:10.1038/s41598-023-32238-8. https://pubmed.ncbi.nlm.nih.gov/36973475/
2. Li, Yuhan, Guo, Beichen, Wang, Lewei, Hong, Wei, Han, Tao. 2023. TEDC2 plays an oncogenic role and serves as a therapeutic target of hepatocellular carcinoma. In Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver, 56, 861-871. doi:10.1016/j.dld.2023.09.025. https://pubmed.ncbi.nlm.nih.gov/37867019/
3. Huang, Chao, He, Jun, Dong, Yi, Peng, Anquan, Huang, Hao. 2022. Identification of Novel Prognostic Markers Associated With Laryngeal Squamous Cell Carcinoma Using Comprehensive Analysis. In Frontiers in oncology, 11, 779153. doi:10.3389/fonc.2021.779153. https://pubmed.ncbi.nlm.nih.gov/35087752/
4. Miyake, Noriko, Shiga, Kentaro, Hasegawa, Yuya, Ito, Shuichi, Matsumoto, Naomichi. 2025. Biallelic TEDC1 variants cause a new syndrome with severe growth impairment and endocrine complications. In European journal of human genetics : EJHG, , . doi:10.1038/s41431-025-01802-3. https://pubmed.ncbi.nlm.nih.gov/39979680/
智鼠故事 
